Indication
In combination with gemcitabine and cisplatin for the first-line treatment of adult patients with recurrent, not amenable to curative surgery or radiotherapy, or metastatic nasopharyngeal carcinoma (NPC).
Medicine details
- Medicine name:
- tislelizumab (Tevimbra)
- SMC ID:
- SMC3020
- Pharmaceutical company
- BeOne Medicines UK Ltd (formerly BeiGene UK Ltd)
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC